Bayer preps for phase 2 after Parkinson's cell therapy clears safety bar in early-stage study

Things are continuing to look up for Bayer’s Parkinson’s disease cell therapy, with the German pharma giant finally offering a deeper dive into phase 1 data that confirms the candidate hit its key safety endpoints.